| P2093 | author name string | Doron Garfinkel | |
| P2860 | cites work | Treatment blood pressure targets for hypertension | Q24239956 |
| | Evidence based medicine: a movement in crisis? | Q24289042 |
| | Evidence based medicine: what it is and what it isn't | Q24655756 |
| | Routine deprescribing of chronic medications to combat polypharmacy | Q26775802 |
| | STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. | Q27000774 |
| | A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice | Q28078344 |
| | Frailty in older adults: evidence for a phenotype | Q28205094 |
| | American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults | Q28268234 |
| | The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea | Q28468452 |
| | 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 |
| | Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia | Q33721869 |
| | Interface between authorship, industry and science in the domain of therapeutics | Q34210129 |
| | Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study | Q34304152 |
| | Clinical consequences of polypharmacy in elderly | Q34373798 |
| | Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance | Q34441791 |
| | Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. | Q34452703 |
| | Relationships between authors of clinical practice guidelines and the pharmaceutical industry | Q34520801 |
| | Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes | Q34639755 |
| | Drug burden index score and functional decline in older people | Q35687146 |
| | Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems | Q36024341 |
| | Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework: a systematic review. | Q36222903 |
| | Optimising drug treatment for elderly people: the prescribing cascade | Q36246842 |
| | Reconsidering medication appropriateness for patients late in life | Q36433390 |
| | The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples | Q36496681 |
| | The medication appropriateness index at 20: where it started, where it has been, and where it may be going | Q37318649 |
| | Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. | Q37378459 |
| | Comparison of published explicit criteria for potentially inappropriate medications in older adults | Q37810592 |
| | Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population | Q37838861 |
| | Minimizing inappropriate medications in older populations: a 10-step conceptual framework | Q37990090 |
| | Patient barriers to and enablers of deprescribing: a systematic review | Q38126375 |
| | Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program | Q38145914 |
| | Drug cessation in complex older adults: time for action | Q38162175 |
| | A medication review and deprescribing method for hospitalised older patients receiving multiple medications. | Q38589894 |
| | Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people | Q38949028 |
| | Reducing inappropriate polypharmacy: the process of deprescribing | Q39026437 |
| | Preventing overdiagnosis: how to stop harming the healthy | Q39611415 |
| | Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. | Q39706971 |
| | The health care cost of drug-related morbidity and mortality in nursing facilities | Q41650837 |
| | The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study | Q42152671 |
| | Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). | Q44242954 |
| | Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study | Q44881260 |
| | Medicare beneficiaries' costs of care in the last year of life | Q44882560 |
| | The Ethics of Deprescribing in Older Adults | Q47698296 |
| | Patient perceptions of proactive medication discontinuation. | Q48167765 |
| | Beyond diagnosis: rising to the multimorbidity challenge. | Q48428947 |
| | Community-dwelling older people's attitudes towards deprescribing in Canada | Q50144545 |
| | Drug-related morbidity and mortality: updating the cost-of-illness model. | Q50673371 |
| | Evidence, guidelines, performance incentives, complexity, and old people: a clinician's dilemma. | Q50757615 |
| | VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. | Q50940664 |
| | The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. | Q51103910 |
| | Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. | Q51649241 |
| | Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. | Q51878686 |
| | [Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly]. | Q52922478 |
| | Are older adults who volunteer to participate in an exercise study fitter and healthier than nonvolunteers? The participation bias of the study population. | Q53118434 |
| | The end of the disease era. | Q53357290 |
| | Winding back the harms of too much medicine | Q57274283 |
| | The challenge of overdiagnosis begins with its definition | Q57497922 |
| | A Prescribing Cascade Involving Cholinesterase Inhibitors and Anticholinergic Drugs | Q58070614 |
| | Knowing How to Stop: Ceasing Prescribing When the Medicine Is No Longer Required | Q61788234 |
| | The Effects of Polypharmacy in Older Adults | Q61828922 |
| | Trends in Medicare payments in the last year of life | Q70617599 |
| | The anticholinergic risk scale and anticholinergic adverse effects in older persons | Q80848672 |
| | Potential pitfalls of disease-specific guidelines for patients with multiple conditions | Q81213097 |
| | Selection bias of elderly patients with chronic angina referred for catheterization | Q81353427 |
| | Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension | Q83324647 |
| | Palliative and therapeutic harmonization: a model for appropriate decision-making in frail older adults | Q85315307 |
| | First do no harm: a real need to deprescribe in older patients | Q85714868 |
| | Patients' perspectives on the brave new word 'deprescribing' | Q86545120 |
| P433 | issue | 1 | |
| P304 | page(s) | 25-43 | |
| P577 | publication date | 2017-10-27 | |
| P1433 | published in | Therapeutic advances in drug safety | Q26853818 |
| P1476 | title | Poly-de-prescribing to treat polypharmacy: efficacy and safety | |
| P478 | volume | 9 | |